Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

CAR-T Digest - August 2020

6 March 2026: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Servier and Day One Biopharmaceuticals announced a definitive agreement under which Servier will acquire Day One in an all-cash transaction valued at approximately $2.5 billion, expanding Servier’s oncology portfolio and strengthening its position in rare cancers
Under the terms of the deal, Servier will launch a tender offer to acquire all outstanding shares of Day One for $21.50 per share in cash, representing a significant premium over the company’s recent market price and reflecting Servier’s strategic investment in targeted oncology therapies
The acquisition is expected to enhance Servier’s leadership in rare oncology, particularly in pediatric low-grade glioma, while adding a pipeline of targeted therapies spanning early-stage programs through Phase 3 clinical development
By combining Day One’s scientific expertise with Servier’s global development and commercialization capabilities, the companies aim to accelerate the advancement of innovative treatments for patients with rare and life-threatening cancers
The transaction is anticipated to close in the second quarter of 2026, subject to customary conditions including shareholder participation and U.S. antitrust clearance, and will be financed through Servier’s existing cash and investments